Converting benzodiazepine dosages can be complex. This article explains Benzo Converters, their use, and the crucial considerations for safe and effective benzodiazepine management.
What is a Benzo Converter?
A benzo converter, often referred to as a benzodiazepine equivalence calculator, is a tool designed to estimate the equivalent dose between two different benzodiazepines. It helps clinicians and patients understand how dosages of various benzodiazepines compare in terms of their potential effect. For example, if a patient is switching from diazepam to lorazepam, a benzo converter can provide an estimated equivalent dose of lorazepam to maintain a similar therapeutic effect.
The Science Behind Benzo Conversions: More Art Than Exact Science
It’s important to recognize that, unlike opioid conversions which are more firmly established, benzodiazepine equivalence is not as well-defined by scientific evidence. The estimations provided by benzo converters are largely based on:
- Expert Opinion: Many conversion ratios are derived from the consensus of clinical experts in the field.
- Uncited Tables: Published documents and clinical guidelines often include tables of benzodiazepine equivalencies without clear sources or robust data.
- Clinical Practice: Real-world clinical experience and observation contribute to the understanding of how different benzodiazepines compare.
Therefore, while benzo converters are helpful tools, they should be used with caution. The conversions are not absolute and often come with a degree of uncertainty. When discrepancies exist in the literature, it’s common to see a range of possible equivalent doses, highlighting the lack of definitive conversion ratios.
Key Issues to Consider with Benzodiazepine Conversions
Several factors contribute to the complexity and potential inaccuracies of benzodiazepine conversions:
- Varied Durations of Action: Benzodiazepines differ significantly in their half-lives, the presence of active metabolites, and how they accumulate in the body with repeated doses. An ideal conversion would account for these differences, especially when switching between benzodiazepines with short and long half-lives. However, current conversion estimates often fail to capture these nuances and may not accurately reflect the differences between single-dose and multiple-dose scenarios.
- Patient-Specific Factors: Benzo converters typically provide a general estimation and do not consider individual patient characteristics. Factors like liver function, kidney function, age, variations in drug metabolism between individuals, and potential drug interactions can all significantly alter how a person processes and responds to benzodiazepines. These individual differences can change the relative potency and duration of effect of each benzodiazepine, making standardized conversions less reliable.
- Lack of Regulatory Oversight: Unlike opioids, regulatory bodies like the FDA do not mandate that pharmaceutical manufacturers provide benzodiazepine equivalence information in drug packaging. This lack of standardized guidance further contributes to the reliance on less evidence-based sources for conversion ratios.
Given these limitations, it is paramount to emphasize clinical judgment, experience, careful patient monitoring, and dose titration when using benzo converters and managing benzodiazepine therapy. Benzo converters should be seen as starting points, not definitive answers.
Dosage Forms and Bioavailability
Most benzodiazepines in conversion charts and calculators are oral formulations. However, some, like midazolam, lorazepam, and diazepam, are available in both oral and injectable forms. Published benzodiazepine dose conversions primarily stem from studies using oral administration. This means that applying these conversion ratios directly to parenteral (injectable) formulations might not be appropriate.
Bioavailability, the proportion of a drug that enters the circulation when introduced into the body and so is able to have an active effect, varies between benzodiazepines. For example, midazolam has a lower oral bioavailability (around 40%, with a range of 35-75%) due to significant first-pass metabolism in the liver. Other benzodiazepines like lorazepam and diazepam have much higher oral bioavailabilities (greater than 90%).
Benzo converters may or may not account for bioavailability differences. It’s crucial to be aware of this factor, especially when converting to or from benzodiazepines with notable bioavailability variations, like midazolam.
Special Case: IV Midazolam Conversion
The conversion between intravenous (IV) midazolam and lorazepam is a notable exception where more robust research exists. Studies in mechanically ventilated patients suggest a conversion ratio of approximately 2 mg of IV midazolam being equivalent to 1 mg of IV lorazepam. This ratio is partly explained by midazolam’s lower oral bioavailability. However, it’s important to note that this specific conversion is derived from studies involving continuous IV infusions in critically ill patients and may not directly translate to other clinical scenarios.
Phenobarbital and Secobarbital: Barbiturate Considerations
Phenobarbital and secobarbital, while technically barbiturates and not benzodiazepines, are often included in benzo conversion charts. This is mainly due to their use in managing alcohol withdrawal, a condition where benzodiazepines are also frequently used. While barbiturates share some pharmacological similarities with benzodiazepines, they have a less favorable safety profile, particularly with a higher risk of respiratory depression. When considering conversions involving phenobarbital or secobarbital, it is crucial to be aware of these distinct safety profiles.
Conclusion: Responsible Use of Benzo Converters
Benzo converters are valuable tools for estimating benzodiazepine dose equivalency. However, they are not a substitute for sound clinical judgment. Due to the limitations in the evidence base, variability in patient factors, and differences in drug characteristics, it is essential to use benzo converters cautiously. Always prioritize patient-specific needs, clinical context, careful monitoring, and gradual dose titration when managing benzodiazepine therapy. Benzo converters should serve as an aid in clinical decision-making, not a definitive guide.
[1] Ashton H. Benzodiazepines: how they work and how to withdraw. Newcastle upon Tyne: Ashton Publishing; 2002.
[2] Shader RI, Greenblatt DJ, Ciraulo DA. Benzodiazepine plasma concentrations after oral and intramuscular administration. J Clin Pharmacol. 1977 Feb-Mar;17(2-3):49-55.
[3] Greenblatt DJ, Shader RI, Franke K, MacLaughlin DS. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci. 1979 Dec;68(12):57-63.
[4] Mandelli M, Tonn G, Nardini M, Morselli PL. Comparative pharmacokinetic study of diazepam after single dose oral, intramuscular and intravenous administration in man. Int J Clin Pharmacol Biopharm. 1978 Jan;16(1):35-41.
[5] Klotz U, Antonin KH, Bieck PR. Pharmacokinetics and bioavailability of diazepam tablets. Clin Pharmacol Ther. 1975 Aug;17(2):231-5.
[6] Greenblatt DJ, Shader RI, Koch-Weser J. Slow absorption of intramuscular chlordiazepoxide. N Engl J Med. 1974 Oct 3;291(14):111-3.
[7] Mahler DL, Forrest WH Jr. Comparative analgesic effects of morphine sulfate and hydromorphone hydrochloride in man. Anesthesiology. 1975 Jul;42(1):3-7.
[8] Sasyniuk BI, Grande P, LeLorier J. Effect of amiodarone on ouabain toxicity in dogs. Circulation. 1973 Jul;48(1):117-22.
[9] Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Manfredi RL, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984 Feb;60(2):234-41.
[10] Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther. 1981 Jul;30(1):653-61.
[11] Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI. Lorazepam kinetics in the elderly. Clin Pharmacol Ther. 1983 Apr;33(4):242-6.
[12] Kaplan SA, Jack ML, Alexander K, Weinfeld RE, Savard K, Porter J, et al. Pharmacokinetic profile of diazepam in man following rapid intravenous and oral administration. J Pharm Sci. 1973 Oct;62(10):1639-44.
[13] Van der Kleijn E, van Rossum JM. Pharmacokinetics of diazepam in dogs, mice and man. Acta Pharmacol Toxicol (Copenh). 1969;27(5):385-96.
[14] Boxenbaum HG, Geitner KA, Jack ML, Dixon WR, Spiegel HE, Symington J, et al. Pharmacokinetics of diazepam in dogs and monkeys as determined by stable isotope methodology. Drug Metab Dispos. 1977 Jan-Feb;5(1):25-31.
[15] Lous P. Plasma levels and urinary excretion of phenobarbital in man. Acta Pharmacol Toxicol (Copenh). 1954;10(2):147-56.
[16] Shelton DK, Kahn CM, Marks ES, Bajaj L, McGovern T, Papadopoulos J, et al. Equivalency of lorazepam and midazolam infusions in critically ill adults. Crit Care Med. 2003 Dec;31(12):2743-8.
